These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36578804)

  • 21. Using a semi-mechanistic model to identify the main sources of variability of metformin pharmacokinetics.
    Stage TB; Wellhagen G; Christensen MMH; Guiastrennec B; Brøsen K; Kjellsson MC
    Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):105-114. PubMed ID: 30267605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus.
    Saito M; Kaibara A; Kadokura T; Toyoshima J; Yoshida S; Kazuta K; Ueyama E
    Br J Clin Pharmacol; 2019 Aug; 85(8):1808-1819. PubMed ID: 31026084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring metformin in cardiac patients exposed to contrast media using ultra-high-performance liquid chromatography tandem mass-spectrometry.
    Radwan MA; Al Taweel ES; Al-Moghairi AM; Aloudah NM; Al Babtain MA; Al-Amri HS
    Ther Drug Monit; 2011 Dec; 33(6):742-9. PubMed ID: 22105592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies.
    Illamola SM; Colom H; van Hasselt JG
    Br J Clin Pharmacol; 2016 Sep; 82(3):793-805. PubMed ID: 27198625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A population pharmacokinetic model for individualised dosage regimens of vancomycin in Chinese neonates and young infants.
    Song L; He CY; Yin NG; Liu F; Jia YT; Liu Y
    Oncotarget; 2017 Dec; 8(62):105211-105221. PubMed ID: 29285245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population Pharmacokinetic Model-Based Evaluation of Standard Dosing Regimens for Cefuroxime Used in Coronary Artery Bypass Graft Surgery with Cardiopulmonary Bypass.
    Alqahtani SA; Alsultan AS; Alqattan HM; Eldemerdash A; Albacker TB
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetics and dosing optimization of metformin in Chinese patients with type 2 diabetes mellitus.
    Li L; Guan Z; Li R; Zhao W; Hao G; Yan Y; Xu Y; Liao L; Wang H; Gao L; Wu K; Gao Y; Li Y
    Medicine (Baltimore); 2020 Nov; 99(46):e23212. PubMed ID: 33181704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women.
    de Oliveira Baraldi C; Moisés EC; de Jesus Ponte Carvalho TM; de Jesus Antunes N; Lanchote VL; Duarte G; Cavalli RC
    Clin Pharmacokinet; 2012 Nov; 51(11):743-9. PubMed ID: 23018469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus.
    Duong JK; Kumar SS; Furlong TJ; Kirkpatrick CM; Graham GG; Greenfield JR; Williams KM; Day RO
    Br J Clin Pharmacol; 2015 Apr; 79(4):617-23. PubMed ID: 25291501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population Pharmacokinetics of
    Jang JH; Jeong SH; Cho HY; Lee YB
    Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31614996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus.
    Fediuk DJ; Zhou S; Dawra VK; Sahasrabudhe V; Sweeney K
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):696-706. PubMed ID: 33205593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus.
    Hong Y; Rohatagi S; Habtemariam B; Walker JR; Schwartz SL; Mager DE
    J Clin Pharmacol; 2008 Jun; 48(6):696-707. PubMed ID: 18372428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A review of population pharmacokinetic models of gentamicin in paediatric patients.
    Crcek M; Zdovc J; Kerec Kos M
    J Clin Pharm Ther; 2019 Oct; 44(5):659-674. PubMed ID: 31102287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal function markers and metformin eligibility.
    Tavares Bello C; Castro Fonseca R; Sousa Santos F; Sequeira Duarte J; Azinheira J; Vasconcelos C
    Minerva Endocrinol; 2018 Sep; 43(3):246-252. PubMed ID: 28565889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
    Herman GA; Bergman A; Yi B; Kipnes M;
    Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus.
    Retlich S; Duval V; Graefe-Mody U; Friedrich C; Patel S; Jaehde U; Staab A
    Clin Pharmacokinet; 2015 Jul; 54(7):737-50. PubMed ID: 25637172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphism in human organic cation transporters and metformin action.
    Takane H; Shikata E; Otsubo K; Higuchi S; Ieiri I
    Pharmacogenomics; 2008 Apr; 9(4):415-22. PubMed ID: 18384255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
    He YL
    Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin.
    de Winter W; Dunne A; de Trixhe XW; Devineni D; Hsu CH; Pinheiro J; Polidori D
    Br J Clin Pharmacol; 2017 May; 83(5):1072-1081. PubMed ID: 28138980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploratory population pharmacokinetics (e-PPK) analysis for predicting human PK using exploratory ADME data during early drug discovery research.
    Tabata K; Hamakawa N; Sanoh S; Terashita S; Teramura T
    Eur J Drug Metab Pharmacokinet; 2009; 34(2):117-28. PubMed ID: 19645221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.